top of page

ASCO 2026: Celcuity CEO Brian Sullivan discusses the late breaking data for the PAM inhibitor gedatolisib that was just presented at ASCO - doubled the likelihood of survival in HR+/HER2- breast

  • Jun 2
  • 1 min read

These data were for patients with the PIK3CA mutation. The median PFS for the gedatolisib triplet combo was 11.1 months versus 5.6 months, compared to alpelisib plus fulvestrant.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page